Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Lisata Therapeutics, Inc. Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events October 31, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis October 28, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events October 03, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial September 17, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events September 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma September 05, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 August 05, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma July 16, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model July 10, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial June 13, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events May 28, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer May 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events May 08, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 May 02, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma April 23, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma April 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events April 03, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma March 21, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time February 22, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Present at BIO CEO & Investor Conference February 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 17, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy January 04, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma December 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Present at NobleCon19 Investor Conference November 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Announces Participation in Upcoming Conferences in November November 09, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time October 26, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Tickers LSTA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
